Sign In
Buy AGIO
$27.68
+1.17 (+4.41%)
At Close: Jun 03, 2026
Agios' PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in the United Arab Emirates
07:00am, Monday, 02'nd Mar 2026
PYRUKYND is the only medicine approved in the UAE for adults with non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia NewBridge Pharmaceuticals, a regional specialty compa
Agios Stock Down 16% in a Year as Fund Cuts Stake by $5.6 Million After 50% November Crash
03:38pm, Tuesday, 17'th Feb 2026
Rock Springs Capital Management sold 159,379 Agios Pharmaceuticals shares in the fourth quarter; the estimated trade size was $5.59 million based on average fourth-quarter prices. Meanwhile, the quart
Agios Pharmaceuticals Incurs Narrower-Than-Expected Q4 Loss
11:36am, Friday, 13'th Feb 2026
AGIO beats fourth-quarter estimates for both the top and bottom lines as Pyrukynd sales jump 49% year over year.
Agios Pharmaceuticals, Inc. (AGIO) Q4 2025 Earnings Call Transcript
05:04pm, Thursday, 12'th Feb 2026
Agios Pharmaceuticals, Inc. (AGIO) Q4 2025 Earnings Call Transcript
Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Beats Revenue Estimates
08:40am, Thursday, 12'th Feb 2026
Agios Pharmaceuticals (AGIO) came out with a quarterly loss of $1.85 per share versus the Zacks Consensus Estimate of a loss of $1.97. This compares to a loss of $1.74 per share a year ago.
Agios Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
06:30am, Thursday, 12'th Feb 2026
PYRUKYND® (mitapivat) worldwide net revenues of $20.0 million in fourth quarter and $54.0 million for full year AQVESME™ (mitapivat) for thalassemia now available in U.S. following FDA approval Com
Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
11:01am, Thursday, 05'th Feb 2026
Agios Pharmaceuticals (AGIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Agios to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call and Webcast on February 12 at 8:00 a.m. ET
07:00am, Monday, 26'th Jan 2026
CAMBRIDGE, Mass., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients wit
Agios Pharmaceuticals, Inc. (AGIO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
02:36pm, Wednesday, 14'th Jan 2026
Agios Pharmaceuticals, Inc. (AGIO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Agios Outlines 2026 Strategic Priorities and Key Milestones to Accelerate Rare Disease Portfolio Growth
07:00am, Monday, 12'th Jan 2026
AQVESME™ (mitapivat) U.S. commercial launch in thalassemia underway following December 2025 FDA approval Pre-sNDA meeting with FDA for mitapivat in sickle cell disease anticipated in first quarter o
Agios to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026
07:00am, Monday, 05'th Jan 2026
Agios today announced that its management team is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026
Agios Pharmaceuticals (NASDAQ:AGIO) CEO Brian Goff Sells 18,703 Shares
05:38am, Saturday, 03'rd Jan 2026
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO - Get Free Report) CEO Brian Goff sold 18,703 shares of the company's stock in a transaction that occurred on Tuesday, December 30th. The shares were sold at
Agios Pharmaceuticals (AGIO) Surges 18.6%: Is This an Indication of Further Gains?
09:46am, Friday, 26'th Dec 2025
Agios Pharmaceuticals (AGIO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strengt
Agios Pharmaceuticals, Inc. (AGIO) Discusses FDA Approval of AQVESME for Anemia in Alpha and Beta Thalassemia Transcript
04:56pm, Wednesday, 24'th Dec 2025
Agios Pharmaceuticals, Inc. (AGIO) Discusses FDA Approval of AQVESME for Anemia in Alpha and Beta Thalassemia Transcript
Agios Pharma Stock: A Buy After FDA Approves Aqvesme
12:48pm, Wednesday, 24'th Dec 2025
Agios Pharmaceuticals upgraded to buy (market perform) after FDA approval of Aqvesme for Alpha- or Beta-Thalassemia, despite boxed warning for liver injury. AGIO's commercial upside from thalassemia i
